A phase II/III study to evaluate the safety and efficacy of Trabodenoson in patients with optic neuropathies and degenerative retinal diseases.
Phase of Trial: Phase II/III
Latest Information Update: 31 Mar 2015
At a glance
- Drugs Trabodenoson (Primary)
- Indications Optic nerve disorders; Retinal degeneration
- Focus Adverse reactions; Therapeutic Use
- 31 Mar 2015 Inotek Pharmaceuticals has planned this study in the 2016, according to the company SEC filing report 10-K 2014.
- 31 Mar 2015 New trial record